Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company whose news flow is centered on the development of therapies for oncology, dermatology, neurodegenerative disease, metabolic disease, and inflammatory conditions. Company updates frequently highlight progress across its pipeline, including HT-001 for cancer-therapy–related skin toxicities, HT-KIT for KIT-driven cancers and mast-cell diseases, HT-ALZ for Alzheimer’s disease, and a GDNF-based metabolic program targeting obesity and fatty liver disease.
News releases from Hoth often cover clinical milestones such as Phase 2 trial activity for HT-001 in EGFR-inhibitor–associated rash, first-in-human study preparations, and regulatory developments in the European Union and the United States. The company also reports on FDA designations, including Orphan Drug Designation for HT-KIT, and on IND-enabling progress and preclinical data in systemic mastocytosis and GIST models.
Investors and followers of HOTH stock can also expect updates on intellectual property expansion, including provisional patent filings and international patent protection related to HT-001 and other programs. Hoth regularly announces collaborations and research partnerships, such as its VA-backed GDNF study at the Atlanta VA Medical Center and participation in NVIDIA’s AI-focused programs to support computational biology and predictive modeling.
This news page aggregates Hoth Therapeutics’ press releases and related coverage, providing a single place to review developments in its clinical trials, regulatory interactions, AI-enabled research initiatives, conference presentations, and corporate communications. Readers interested in the evolution of HOTH’s pipeline and regulatory strategy can use this feed to monitor ongoing announcements and historical updates.
Hoth Therapeutics (Nasdaq: HOTH) closed a registered direct offering on April 2, 2026, selling 2,857,144 shares at $0.70 per share for gross proceeds of approximately $2.0 million. Concurrently, the company sold unregistered warrants exercisable at $0.85 after six months and expiring 5.5 years after issuance. H.C. Wainwright acted as placement agent. The company intends to use net proceeds for general corporate purposes, including working capital.
Hoth Therapeutics (Nasdaq: HOTH) agreed to sell 2,857,144 shares at $0.70 per share in a registered direct offering, raising approximately $2.0 million gross before fees. A concurrent private placement issued warrants to buy 2,857,144 shares at $0.85, exercisable six months after issuance and expiring 5.5 years later. Closing expected on or about April 2, 2026. Proceeds intended for general corporate purposes, including working capital; placement agent H.C. Wainwright & Co. is exclusive agent.
Hoth Therapeutics (NASDAQ: HOTH) reported that its HT-001 program met the primary efficacy endpoint in an interim analysis, with patients reaching an ARIGA ≤1 by week six. Over 65% of patients reported reduced pain and itching, with zero EGFR therapy disruptions and ~99% lower systemic exposure versus oral therapies. Hungary approved expansion of the Phase 2 trial into Europe, and site activations are expected soon in the U.S., Spain and Poland.
Hoth Therapeutics (NASDAQ: HOTH) announced that the China National Intellectual Property Administration granted a Chinese patent titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells".
The patent (PCT/US2019/048400), developed by North Carolina State University, provides protection in China through August 27, 2039, subject to maintenance requirements, and covers a splice-switching oligonucleotide platform that selectively induces mast cell apoptosis.
Hoth Therapeutics (NASDAQ: HOTH) announced deployment of OpenClaw™, an AI-enabled computational platform to accelerate drug discovery across its pipeline.
OpenClaw™ centralizes preclinical and clinical data in real time, standardizes workflows across dermatology, oncology and inflammatory programs, and is designed to speed candidate selection and increase probability of technical success, the company said.
Hoth Therapeutics (NASDAQ: HOTH) reported positive pharmacokinetic, safety, and clinical activity data for topical HT-001 on March 24, 2026. Key PK results: mean AUC₀–₂₄ rose to 80.60 h•ng/mL on Day 42 from 45.61 on Day 1 (~76.7% increase). Mean Cavg increased to 3.36 ng/mL and mean Cmax to 4.56 ng/mL. Accumulation ratios were RA_AUCτ ~2.09x and RA_Cmax ~1.72x. Systemic exposure remained minimal versus oral formulations (~0.2% Day 1, 0.5% Day 42). Safety: no serious adverse events, no dose-limiting toxicities, and no discontinuations due to adverse events. The company linked sustained exposure to observed symptom reductions and supports further development and dose optimization.
Hoth Therapeutics (NASDAQ: HOTH) reported female-specific preclinical data showing its GDNF candidate HT-VA restored serum cholesterol to control-diet levels and maintained lower triglycerides versus semaglutide in western diet–fed female mice. The treatment preserved hepatic autophagy and showed no activation of lipogenesis or pAKT signaling.
Study used female mice (8–10 per group) with eight weeks of diet and four weeks of treatment; results support continued development for MASLD and metabolic dysfunction associated with obesity.
Hoth Therapeutics (NASDAQ: HOTH) deployed the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy for rare KIT-driven cancers. Key preclinical findings include >80% KIT mRNA/protein suppression, statistically significant tumor-volume reduction by Day 8, and no dose-limiting toxicities reported.
GLP-validated bioanalytical methods are complete and HT-KIT is advancing toward IND submission and Phase 1 clinical evaluation.
Hoth Therapeutics (NASDAQ: HOTH) announced expansion of its CLEER-001 Phase 2a trial with a new enrolling site, Regis Clinical Research in Miami, on Feb 24, 2026.
Interim data show 100% of open-label cohort met the primary ARIGA ≤1 endpoint by week six, 0 dose reductions, >65% meaningful pain/itch relief, and 0 dose-limiting toxicities; the company said the new site will speed enrollment and data collection.
Hoth Therapeutics (NASDAQ: HOTH) received a Notice of Allowance from the USPTO on February 12, 2026, for a patent titled "Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases."
The allowed claims cover a dual-mechanism approach—exon skipping in the high-affinity IgE receptor pathway and modulation of MS4A6A—positioning Hoth to expand its immunology IP, pursue partnerships, and strengthen long-term defensibility in allergic and inflammatory disease markets.